Barbara J Bullock
Examiner (ID: 17427)
Most Active Art Unit | 2901 |
Art Unit(s) | 2901, 2902, 2900, 2912 |
Total Applications | 4468 |
Issued Applications | 4372 |
Pending Applications | 0 |
Abandoned Applications | 96 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 18916870
[patent_doc_number] => 11879141
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-23
[patent_title] => Nucleic acid molecules encoding clostridium histolyticum collagenase II and methods of producing the same
[patent_app_type] => utility
[patent_app_number] => 18/342874
[patent_app_country] => US
[patent_app_date] => 2023-06-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 28
[patent_figures_cnt] => 24
[patent_no_of_words] => 16626
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18342874
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/342874 | Nucleic acid molecules encoding clostridium histolyticum collagenase II and methods of producing the same | Jun 27, 2023 | Issued |
Array
(
[id] => 18769487
[patent_doc_number] => 20230364256
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-16
[patent_title] => ANTIBODY OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF INDUCING DMD EXON 44 SKIPPING
[patent_app_type] => utility
[patent_app_number] => 18/130757
[patent_app_country] => US
[patent_app_date] => 2023-04-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35730
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18130757
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/130757 | ANTIBODY OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF INDUCING DMD EXON 44 SKIPPING | Apr 3, 2023 | Pending |
Array
(
[id] => 18522996
[patent_doc_number] => 20230233649
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => IL-15-BASED MOLECULES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/175112
[patent_app_country] => US
[patent_app_date] => 2023-02-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30613
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18175112
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/175112 | Method for treating neoplasia with an anti-CD38 antibody and an IL-15:IL-15R complex | Feb 26, 2023 | Issued |
Array
(
[id] => 18754029
[patent_doc_number] => 20230357396
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-09
[patent_title] => MONOCLONAL ANTIBODIES AND METHODS FOR USING SAME
[patent_app_type] => utility
[patent_app_number] => 18/103194
[patent_app_country] => US
[patent_app_date] => 2023-01-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15857
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18103194
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/103194 | MONOCLONAL ANTIBODIES AND METHODS FOR USING SAME | Jan 29, 2023 | Pending |
Array
(
[id] => 18626705
[patent_doc_number] => 20230285507
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-14
[patent_title] => COMPOSITIONS AND METHODS FOR CARDIAC TISSUE REPAIR
[patent_app_type] => utility
[patent_app_number] => 18/159556
[patent_app_country] => US
[patent_app_date] => 2023-01-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16433
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18159556
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/159556 | COMPOSITIONS AND METHODS FOR CARDIAC TISSUE REPAIR | Jan 24, 2023 | Pending |
Array
(
[id] => 18510108
[patent_doc_number] => 20230226209
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-20
[patent_title] => ANTIBODY ENDOHEDRAL METALLOFULLERENE CONJUGATE AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/156617
[patent_app_country] => US
[patent_app_date] => 2023-01-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7550
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 119
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18156617
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/156617 | ANTIBODY ENDOHEDRAL METALLOFULLERENE CONJUGATE AND USES THEREOF | Jan 18, 2023 | Pending |
Array
(
[id] => 18830863
[patent_doc_number] => 20230399388
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-14
[patent_title] => METHODS FOR TREATING INFLAMMATION USING ANTIBODIES TO KALLIDIN AND DES-ARG10-KALLIDIN
[patent_app_type] => utility
[patent_app_number] => 18/063981
[patent_app_country] => US
[patent_app_date] => 2022-12-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28849
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18063981
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/063981 | METHODS FOR TREATING INFLAMMATION USING ANTIBODIES TO KALLIDIN AND DES-ARG10-KALLIDIN | Dec 8, 2022 | Pending |
Array
(
[id] => 18692579
[patent_doc_number] => 20230322880
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-12
[patent_title] => IL-7RALPHA-GAMMA LIGAND IMMUNOGLOBULIN FUSION PROTEINS
[patent_app_type] => utility
[patent_app_number] => 18/061567
[patent_app_country] => US
[patent_app_date] => 2022-12-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27739
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 64
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18061567
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/061567 | IL-7RALPHA-GAMMA LIGAND IMMUNOGLOBULIN FUSION PROTEINS | Dec 4, 2022 | Pending |
Array
(
[id] => 18529946
[patent_doc_number] => 20230235013
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => MODIFIED IMMUNOGLUBIN FC REGIONS
[patent_app_type] => utility
[patent_app_number] => 18/057420
[patent_app_country] => US
[patent_app_date] => 2022-11-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35079
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 131
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18057420
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/057420 | MODIFIED IMMUNOGLUBIN FC REGIONS | Nov 20, 2022 | Pending |
Array
(
[id] => 18253532
[patent_doc_number] => 20230080571
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-16
[patent_title] => PHARMACEUTICAL FORMULATIONS AND METHODS OF MAKING THE SAME
[patent_app_type] => utility
[patent_app_number] => 17/933055
[patent_app_country] => US
[patent_app_date] => 2022-09-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13197
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17933055
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/933055 | PHARMACEUTICAL FORMULATIONS AND METHODS OF MAKING THE SAME | Sep 15, 2022 | Pending |
Array
(
[id] => 18582906
[patent_doc_number] => 20230265163
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-24
[patent_title] => SWITCH RECEPTORS USING IL-9 SIGNALING DOMAINS
[patent_app_type] => utility
[patent_app_number] => 17/946916
[patent_app_country] => US
[patent_app_date] => 2022-09-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21767
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 57
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17946916
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/946916 | SWITCH RECEPTORS USING IL-9 SIGNALING DOMAINS | Sep 15, 2022 | Pending |
Array
(
[id] => 18510078
[patent_doc_number] => 20230226177
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-20
[patent_title] => LOW-VISCOSITY, HIGH CONCENTRATION EVOLOCUMAB FORMULATIONS AND METHODS OF MAKING THE SAME
[patent_app_type] => utility
[patent_app_number] => 17/893515
[patent_app_country] => US
[patent_app_date] => 2022-08-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43718
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17893515
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/893515 | LOW-VISCOSITY, HIGH CONCENTRATION EVOLOCUMAB FORMULATIONS AND METHODS OF MAKING THE SAME | Aug 22, 2022 | Pending |
Array
(
[id] => 18160948
[patent_doc_number] => 20230027540
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-26
[patent_title] => IL-12 HETERODIMERIC FC-FUSION PROTEINS
[patent_app_type] => utility
[patent_app_number] => 17/886103
[patent_app_country] => US
[patent_app_date] => 2022-08-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 83121
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 89
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17886103
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/886103 | IL-12 heterodimeric Fc-fusion proteins | Aug 10, 2022 | Issued |
Array
(
[id] => 18165693
[patent_doc_number] => 20230032293
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-02
[patent_title] => KIT FOR PREPARING DISEASE-TREATING AGENT, DISEASE-TREATING AGENT AND METHOD FOR PREPARING DISEASE-TREATING AGENT
[patent_app_type] => utility
[patent_app_number] => 17/881413
[patent_app_country] => US
[patent_app_date] => 2022-08-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11771
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 65
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17881413
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/881413 | KIT FOR PREPARING DISEASE-TREATING AGENT, DISEASE-TREATING AGENT AND METHOD FOR PREPARING DISEASE-TREATING AGENT | Aug 3, 2022 | Pending |
Array
(
[id] => 18321679
[patent_doc_number] => 20230119807
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-20
[patent_title] => ASTROTACTIN1-BASED COMPOSITIONS AND PHARMACEUTICAL FORMULATIONS
[patent_app_type] => utility
[patent_app_number] => 17/873083
[patent_app_country] => US
[patent_app_date] => 2022-07-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12058
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17873083
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/873083 | ASTROTACTIN1-BASED COMPOSITIONS AND PHARMACEUTICAL FORMULATIONS | Jul 24, 2022 | Pending |
Array
(
[id] => 18449653
[patent_doc_number] => 20230190929
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => ANTI-PRO/LATENT-MYOSTATIN ANTIBODIES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/814221
[patent_app_country] => US
[patent_app_date] => 2022-07-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39556
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17814221
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/814221 | ANTI-PRO/LATENT-MYOSTATIN ANTIBODIES AND USES THEREOF | Jul 20, 2022 | Pending |
Array
(
[id] => 17988921
[patent_doc_number] => 20220354958
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-10
[patent_title] => POLYPEPTIDE-FC CONJUGATE WITH ATTENUATED IMMUNE RESPONSE
[patent_app_type] => utility
[patent_app_number] => 17/866188
[patent_app_country] => US
[patent_app_date] => 2022-07-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15934
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 115
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17866188
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/866188 | POLYPEPTIDE-FC CONJUGATE WITH ATTENUATED IMMUNE RESPONSE | Jul 14, 2022 | Pending |
Array
(
[id] => 17958673
[patent_doc_number] => 20220339253
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-27
[patent_title] => REDUCING THE RISK OF MAJOR ADVERSE CARDIAC EVENTS
[patent_app_type] => utility
[patent_app_number] => 17/859130
[patent_app_country] => US
[patent_app_date] => 2022-07-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6974
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17859130
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/859130 | REDUCING THE RISK OF MAJOR ADVERSE CARDIAC EVENTS | Jul 6, 2022 | Pending |
Array
(
[id] => 18484970
[patent_doc_number] => 20230212285
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-06
[patent_title] => C-KIT ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 17/810423
[patent_app_country] => US
[patent_app_date] => 2022-07-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29328
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17810423
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/810423 | C-KIT ANTIBODIES | Jun 30, 2022 | Pending |
Array
(
[id] => 18037555
[patent_doc_number] => 20220381771
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-01
[patent_title] => T-CELL REACTIVITY PLATFORM
[patent_app_type] => utility
[patent_app_number] => 17/838863
[patent_app_country] => US
[patent_app_date] => 2022-06-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8635
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17838863
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/838863 | T-CELL REACTIVITY PLATFORM | Jun 12, 2022 | Pending |